Publication date: Available online 7 June 2018
Source:Photodiagnosis and Photodynamic Therapy
Author(s): Aya Ahmed Sebak, Iman Imam Gomaa, Aliaa Nabil ElMeshad, Mahmoud Hashem AbdelKader
BackgroundPhotodynamic therapy (PDT) has been determined to be a promising treatment modality in the most resistant tumors as malignant melanoma. Meanwhile, the key cytotoxic agent of PDT, -singlet oxygen (1O2) - represents a high risk of photodynamic-associated side effects e.g. skin photosensitization. Recently, controllable photosensitization, where 1O2 is produced on demand, has received increasing attention. In our study, this could be achieved via loading the photosensitizer (PS) in nanoparticles (NPs) decorated with target-specific moieties characterized by 1O2 quenching abilities to specifically locate the PS in the targeted cells and assure that 1O2 is only produced where desired after cellular processing.MethodsPolymeric and hybrid lipid-polymer NPs were formulated and assayed for their physicochemical properties. This was followed by conjugation with an active targeting ligand, cRGDyk, cyclic (Arginine-Glycine-Aspartic acid-D-Tyrosine-Lysine) peptide. Finally, photodynamic potential of the selected formulations was assayed by quantification of 1O2 production and in vitro cytotoxicity.ResultsThree formulations were selected and nominated to be formulations of choice (FOCs); FOC-1 (200 nm, polymeric), FOC-2 (130 nm, polymeric) and FOC-3 (200 nm, hybrid). Physicochemical properties, most importantly particle size and NPs' composition have shown to be the major determinants in targeted NPs' 1O2 production and PDT-mediated cytotoxicity of melanoma.ConclusionProper selection of formulations intended for PDT application and target-specific ligands could achieve dual targeting; enhanced accumulation of NPs and protection of 1O2 production elsewhere other than target cells.
Graphical abstract
https://ift.tt/2kVVEL9
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου